Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0001055919 XXXXXXXX LIVE 17 Common Stock, par value $0.001 per share 05/11/2026 false 0001625101 74587B101 Pulse Biosciences, Inc. 601 Brickell Key Drive, Suite 1080 Miami FL 33131 ADAM W. FINERMAN, ESQ. (212) 589-4233 BAKER HOSTETLER LLP 45 Rockefeller Plaza New York NY 10111 0001055919 N ROBERT W. DUGGAN PF N X1 49706423 0 49706423 0 49706423 N 71.9 IN *Represents 49,706,423 shares of Common Stock, including (i) 256,078 shares of Common Stock underlying certain options exercisable within 60 days hereof, held by Mr. Duggan, (ii) 630,109 shares of Common Stock held by Genius 24C Inc d/b/a Genius Inc and (iii) 450,189 shares of Common Stock held by Blazon Corporation. This does not include options which are not exercisable in 60 days from the date hereof. The number of shares of Common Stock beneficially owned by Mr. Duggan reported in the table above does not include shares of Common Stock which are beneficially owned by Mr. Duggan's spouse, Dr. Maky Zanganeh. As spouses, Mr. Duggan and Dr. Zanganeh may be deemed to have acquired beneficial ownership of the securities held by the other spouse upon their marriage on December 18, 2024. Mr. Duggan does not hold any voting or investment power over such securities held by Dr. Zanganeh. Mr. Duggan disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Percent beneficially owned is based on 69,141,378 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, (ii) 256,078 shares underlying options that can be exercised by Mr. Duggan within 60 days hereof and (iii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program. Y GENIUS 24C INC WC N FL 630109 0 630109 0 630109 N 0.9 CO * Represents 630,109 shares of Common Stock held by Genius 24C Inc d/b/a Genius Inc. Percent beneficially owned is based on 68,885,300 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program. Y BLAZON CORPORATION WC N CA 450189 0 450189 0 450189 N 0.7 CO * Represents 450,189 shares of Common Stock held by Blazon Corporation. Percent beneficially owned is based on 68,885,300 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program. Common Stock, par value $0.001 per share Pulse Biosciences, Inc. 601 Brickell Key Drive, Suite 1080 Miami FL 33131 The following constitutes Amendment No. 17 to the Schedule 13D filed by the undersigned. This Amendment No. 17 amends the Schedule 13D as specifically set forth herein. Item 3 is hereby amended and restated to read as follows: The aggregate purchase cost of the 49,706,423 shares of common stock beneficially owned by Mr. Duggan is approximately $414,666,603 including brokerage commissions. Such shares were acquired with personal funds (with the exception of the 630,109 shares owned Genius 24C Inc d/b/a Genius Inc and the 450,189 shares owned by Blazon Corporation. Mr. Duggan received his 256,078 stock options in connection with his service on the board of directors of the Issuer). The aggregate purchase cost of the 630,109 shares of Common Stock owned by Genius 24C Inc d/b/a Genius Inc ("Genius"), which Mr. Duggan is the sole shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $5,957,491.56 including brokerage commissions. Such shares were acquired with working capital. The aggregate purchase cost of the 450,189 shares of Common Stock owned by Blazon Corporation ("Blazon"), which Mr. Duggan is the majority shareholder of and may be deemed to be beneficially owned by Mr. Duggan, is approximately $4,284,178.60 including brokerage commissions. Such shares were acquired with working capital. Items 5(a)-(c) are hereby amended to read as follows: The aggregate percentage of shares of Common Stock reported owned by each person named herein is based upon 68,885,300 shares outstanding consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program, and in the case of Mr. Duggan, an additional 256,078 shares underlying options that can be exercised by Mr. Duggan within 60 days hereof. A. Mr. Duggan As of the close of business on May 11, 2026, Mr. Duggan beneficially owned 49,706,423 shares of Common Stock, including 256,078 shares underlying certain options exercisable within sixty days hereof. As the sole shareholder of Genius, Mr. Duggan may be deemed the beneficial owner of the 630,109 shares of Common Stock held by Genius. As the majority shareholder of Blazon Corporation, Mr. Duggan may be deemed the beneficial owner of the 450,189 shares of Common Stock held by Blazon. Percentage: Approximately 71.9% B. Genius 24C Inc d/b/a Genius Inc As of the close of business on May 11, 2026, Genius beneficially owned 630,109 shares of Common Stock. Percentage: Approximately 0.9% C. Blazon Corporation As of the close of business on May 11, 2026, Blazon Corporation beneficially owned 450,189 shares of Common Stock. Percentage: Approximately 0.7% Item 5(b) is hereby amended to read as follows: A. Mr. Duggan: 1. Sole power to vote or direct vote: 49,706,423 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 49,706,423 4. Shared power to dispose or direct the disposition: 0 B. Genius 24C In d/b/a Genius Inc.: 1. Sole power to vote or direct vote: 630,109 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 630,109 4. Shared power to dispose or direct the disposition: 0 C. Blazon Corporation: 1. Sole power to vote or direct vote: 450,189 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 450,189 4. Shared power to dispose or direct the disposition: 0 Item 5(c) is hereby amended to read as follows: The transactions in the shares of Common Stock by the Reporting Persons during the past sixty days are set forth below in the table entitled "Transactions in the Common Stock During the Past Sixty Days." Transactions in the Common Stock During the Past Sixty Days Reporting Person Type of Security Securities Purchased / (Sold) Price Per Share($) Date of Purchase / Sale Mr. Duggan Common Stock 660,233 19.69(1) 5/11/2026 (1) The shares reported herein were acquired through the Company's at-the-market equity offering program established pursuant to that certain Equity Distribution Agreement, dated February 19, 2026, by and between the Company and TD Securities (USA) LLC, as sales agent. The shares were purchased during an open trading window under the Company's Insider Trading Policy and in accordance with applicable securities laws. The shares reported herein were purchased at the prevailing market bid price or higher at the time of sale. ROBERT W. DUGGAN /s/ Robert W. Duggan Robert W. Duggan 05/13/2026 GENIUS 24C INC /s/ Robert W. Duggan Robert W. Duggan, Authorized Signatory 05/13/2026 BLAZON CORPORATION /s/ Robert W. Duggan Robert W. Duggan, Authorized Signatory 05/13/2026